Sio Gene Therapies is a a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. Co. has three clinical-stage programs: AXO-AAV-GM1 for the treatment of GM1 gangliosidosis; AXO-AAV-GM2 for the treatment of GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases); and AXO-Lenti-PD for the treatment of Parkinson's disease. The SIOX average annual return since 2015 is shown above.
The Average Annual Return on the SIOX average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SIOX average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SIOX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|